Celltrion secures $730 mn to buy biosimilar unit shares, pursue M&A
Celltrion Holdings Co. has secured 1 trillion won ($732 million) in fresh funding and plans to spend half of it this year to buy shares in its biosi...
GEPS taps former KB Asset chief risk officer as new CIO
South Korea’s Government Employees Pension Service (GEPS) on Wednesday appointed Sohn Young-jin, former head of risk management at KB Asset Ma...
Celltrion shares rise after bonus issue announcement
Celltrion Inc., South Korea’s largest biosimilar developer, will issue bonus shares to bolster its stock performance, which has been in the do...
Shinhan Financial’s Jin meets with Goldman Sachs Int'l CEO for strategies
Jin Ok-dong, chairman of South Korea’s leading financial conglomerate Shinhan Financial Group, has met with senior executives of US-based mult...
S.Korea’s Naver to launch Silicon Valley venture arm in aggressive AI push
Naver Corp., South Korea’s top internet portal operator, plans to set up a dedicated venture capital arm in Silicon Valley in a move seen as a...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Trump Jr. to visit Seoul next week to meet Korean business leaders
Donald Trump Jr., the eldest son of the US President Donald Trump, is set to visit Seoul next week and meet with Korean business leaders grappling w...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Naver to build sovereign AI, says founder Lee after return
South Korea’s No. 1 internet portal operator Naver Corp. will build strong sovereign artificial intelligence to fight the growing dominance of...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
Celltrion to cancel $140 mn in treasury shares, stock up
South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Hyundai Motor launches future strategy division overseeing M&As
Hyundai Motor Group has created a future business strategy division that serves as a control tower for the automotive group’s expansion into n...
Naver founder to return as board chair; 2024 earnings solid
Lee Hae-jin, the founder of South Korea’s No. 1 internet portal operator Naver Corp., is set to return to the company to lead the board amid t...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Celltrion BioSolutions launched to venture into CDMO
Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Celltrion to allot cash, stock dividend at once
South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. The company wi...
BTS Jin to enter liquor business
BTS Jin plans to enter Korean traditional liquor business with Baek Jong-won, founder and CEO of The Born Korea Co., the entertainment industry sour...
Samsung foundry ‘relief pitcher’ Han Jin-man vows to improve 2-nm yields
Samsung Electronics Co.'s new contract chipmaking business chief said on Monday he will go all-in to improve the company’s advanced 2-nanomete...
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
Celltrion to retire $400 mn treasury stock in January
South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion ...
Korean Air-Asiana merger to spur M&A among budget carriers
Korean Air Lines Co.'s anticipated acquisition of Asiana Airlines Inc. is expected to spur domestic budget carriers to seek mergers, with the two do...
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Samsung reshuffles top brass; Co-CEO to control memory business
Samsung Electronics Co., the world’s No. 1 memory chipmaker, reshuffled its leadership on Wednesday in a sweeping move as it faces an uph...
